1. Home
  2. MRKR vs FEMY Comparison

MRKR vs FEMY Comparison

Compare MRKR & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • FEMY
  • Stock Information
  • Founded
  • MRKR N/A
  • FEMY 2004
  • Country
  • MRKR United States
  • FEMY United States
  • Employees
  • MRKR N/A
  • FEMY 34
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • FEMY Medical/Dental Instruments
  • Sector
  • MRKR Health Care
  • FEMY Health Care
  • Exchange
  • MRKR Nasdaq
  • FEMY Nasdaq
  • Market Cap
  • MRKR 30.7M
  • FEMY 25.0M
  • IPO Year
  • MRKR N/A
  • FEMY 2021
  • Fundamental
  • Price
  • MRKR $3.44
  • FEMY $1.09
  • Analyst Decision
  • MRKR Strong Buy
  • FEMY Strong Buy
  • Analyst Count
  • MRKR 1
  • FEMY 3
  • Target Price
  • MRKR $19.00
  • FEMY $10.00
  • AVG Volume (30 Days)
  • MRKR 91.1K
  • FEMY 185.8K
  • Earning Date
  • MRKR 11-14-2024
  • FEMY 11-12-2024
  • Dividend Yield
  • MRKR N/A
  • FEMY N/A
  • EPS Growth
  • MRKR N/A
  • FEMY N/A
  • EPS
  • MRKR N/A
  • FEMY N/A
  • Revenue
  • MRKR $5,395,849.00
  • FEMY $1,260,643.00
  • Revenue This Year
  • MRKR $35.94
  • FEMY $157.75
  • Revenue Next Year
  • MRKR N/A
  • FEMY $254.07
  • P/E Ratio
  • MRKR N/A
  • FEMY N/A
  • Revenue Growth
  • MRKR 79.04
  • FEMY 15.33
  • 52 Week Low
  • MRKR $2.44
  • FEMY $0.73
  • 52 Week High
  • MRKR $6.16
  • FEMY $2.40
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 50.16
  • FEMY 46.37
  • Support Level
  • MRKR $3.47
  • FEMY $1.05
  • Resistance Level
  • MRKR $5.95
  • FEMY $1.24
  • Average True Range (ATR)
  • MRKR 0.63
  • FEMY 0.08
  • MACD
  • MRKR 0.01
  • FEMY -0.01
  • Stochastic Oscillator
  • MRKR 16.99
  • FEMY 12.71

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.

Share on Social Networks: